Lead: Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial
Failed to add items
Add to basket failed.
Add to Wish List failed.
Remove from Wish List failed.
Follow podcast failed
Unfollow podcast failed
Lead: Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial
-
Narrated by:
-
By:
About this listen
Varenicline for Youth Nicotine Vaping Cessation: A Randomized Clinical Trial
Journal of the American Medical Association
This 12-week randomized clinical trial in 261 treatment-seeking youth aged 16 to 25 years assessed if varenicline, when added to brief, remotely delivered behavioral support, was efficacious and well tolerated for nicotine vaping cessation in youth. Researchers found that continuous abstinence rates were higher in the varenicline group than in the placebo group in the last month of treatment (51% vs 14%) and at 6-month follow-up (28% vs 7%). Treatment-emergent adverse events did not differ significantly between groups. Varenicline, when added to brief cessation counseling, is well tolerated and promotes nicotine vaping cessation compared with placebo in youth with addiction to vaped nicotine.
Read this issue of the ASAM Weekly
Subscribe to the ASAM Weekly
Visit ASAM